Author:
Ben Mabrouk A.,Ben Brahim H.,Kooli I.,Marrakchi W.,Aouam A.,Loussaief C.,Toumi A.,Chakroun M.
Subject
Pharmaceutical Science,Pharmacology
Reference56 articles.
1. Tigecycline: an update;Stein;Diagn Microbiol Infect Dis,2013
2. Résumé des Caractéristiques du Produit n.d. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0313996.htm (accessed October 5, 2020).
3. Research C for DE and. Drug Safety and Availability FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning n.d.
4. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin;Bergallo;Diagn Microbiol Infect Dis,2009
5. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia;Tanaseanu;BMC Pulm Med,2009
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献